
The House Committee on Oversight and Reform this week concluded a two-day hearing examining pricing practices for some of the nation’s costliest drugs. As part of the hearing, Committee Chairwoman Carolyn Maloney, D-N.Y., released additional staff reports describing repeated actions by drug companies to raise the price of certain drugs.